Introduction {#S0001}
============

Since the introduction of highly active antiretroviral therapy (HAART) as a treatment for HIV and AIDS, HIV-related mortality has been reduced by 50 to 80% \[[@CIT0001]\]. However, HIV-infected individuals on long-term therapy are at increased risk for developing a variety of metabolic disturbances, including fat redistribution, dyslipidemia, insulin resistance, lactic acidemia and abnormalities in bone mineral metabolism, particularly with nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs) \[[@CIT0002]--[@CIT0006]\]. Several of these complications, particularly lipodystrophy, can predispose individuals to cardiovascular disease and impact quality of life and adherence to antiretroviral therapy (ART) \[[@CIT0005],[@CIT0007]--[@CIT0009]\].

Research on metabolic complications of ART has been primarily conducted in high-income countries. There is increasing evidence from low- and middle-income countries evaluating the short- and long-term effects of ART on lipodystrophy syndromes such as lipoatrophy, lipohypertrophy and mixed syndrome. *Lipoatrophy* is the loss of subcutaneous fat, particularly evident in the face, buttocks and limbs. *Lipohypertrophy* is the accumulation of visceral and central fat in the abdomen, dorsocervical region ("buffalo hump"), or breasts. *Fat redistribution* is an all-encompassing terms used to describe lipohypertrophy, lipoatrophy and/or mixed syndrome \[[@CIT0010]--[@CIT0012]\]. In early studies, lipodystrophy was used to describe a syndrome of subcutaneous fat loss with or without visceral fat accumulation, insulin resistance and/or dyslipidemia \[[@CIT0013]\]. Although most studies to date use "lipodystrophy" as an all-encompassing term for fat redistribution, current research emphasizes the need to differentiate isolated lipoatrophy, lipohypertrophy and mixed syndrome as separate disease processes \[[@CIT0013]--[@CIT0015]\]. In this review, fat redistribution syndromes will be defined based on clinical guidelines and as defined by study authors.

In the context of rapid ART scale-up in resource-limited settings, addressing lipodystrophy is a critical component of HIV/AIDS care and treatment. The antiretroviral (ARV) medications linked to lipodystrophy, particularly lipoatrophy, are prevalent in low-income and middle-income settings \[[@CIT0016]\], where HIV-infected populations face the dual burden of obesity and undernutrition \[[@CIT0017],[@CIT0018]\]. There is a need to evaluate the prevalence, pathogenesis and prognosis of lipoatrophy, lipohypertrophy and mixed syndrome, to inform clinical management in low- and middle-income countries.

Methods {#S0002}
=======

Search strategy {#S0002-S20001}
---------------

We conducted a structured literature search using MEDLINE electronic databases to identifiy published studies through 31 March 2014. Search terms included: (HIV \[MH\] OR HIV Infect\*\[MH\] OR Human Immunodeficiency Virus \[tw\] OR Human Immuno-deficiency Virus \[tw\] OR hiv-1 \[tw\] OR hiv-2 \[tw\] OR hiv\*\[tw\] OR AIDS \[MH\] OR AIDS \[tw\]) AND (Lipodystrophy \[MH\] OR Lipoatrophy \[MH\] OR -hypertrophy \[MH\] OR buffalo hump \[tw\] OR lipo-accumulation \[tw\] OR lipo\*\[MH\] OR adiposity \[tw\] OR Lipodystrophy \[tw\] OR Lipoatrophy \[tw\] OR Lipohypertrophy \[tw\] or Fat distrib\*\[tw\] or Fat redistrib\*\[tw\] OR fat accumulation \[tw\] or lipo-\*\[tw\]) \[[@CIT0019]\]. The search strategy and results are summarized in [Figure 1](#F0001){ref-type="fig"}, and findings from these studies are summarized in detail in the supplementary tables ([Tables 1](#T0003){ref-type="table"}--[3](#T0003){ref-type="table"}).

![Search strategy.](JIAS-18-19033-g001){#F0001}

The structured literature search resulted in 5296 articles; after 1599 studies were excluded (958 reviews, 641 non-human), 3697 studies were extracted for further review. Sources were retrieved, collected, indexed and assessed for HIV- and lipodystrophy-related data. The inclusion criteria for this review were availability of data on human HIV-related fat redistribution (lipodystrophy, lipoatrophy, fat redistribution, lipo-accumulation and/or lipohypertrophy), abstract availability, age ≥18 years, and low-, low-middle- and upper-middle-income countries, as defined by the World Bank classification \[[@CIT0020]\].

After excluding studies conducted in high-income settings (*n*=2808), and studies that did not meet inclusion criteria (*n*=799), 90 studies were included in this review. These included 28 from Africa, 26 from Asia and 36 from Latin America.

Literature review {#S0003}
=================

Prevalence of lipodystrophy {#S0003-S20001}
---------------------------

The global prevalence of lipodystrophy among HIV-infected adults on ART ranges considerably, from less than 1 to 84% \[[@CIT0004],[@CIT0012],[@CIT0021]--[@CIT0041]\]. The burden of HIV-related lipodystrophy is estimated to be high in low- and middle-income countries \[[@CIT0004],[@CIT0012],[@CIT0024]--[@CIT0041]\], with an incidence of 1.4 to 20.6 per 100 person-years \[[@CIT0033],[@CIT0042],[@CIT0043]\], and 6.7 to 22.1 per 100 person-years \[[@CIT0027],[@CIT0032]\], in studies in Asia and Africa, respectively. The wide ranges in prevalence reflect variations in study design, gender balance in studies, types of ARVs and duration of therapy. Understanding the major risks factors for lipodystrophy, lipoatrophy, lipohypertrophy and mixed syndrome may help explain the wide range in prevalence around the world and inform prevention and clinical management. Lipodystrophy may develop within four to six months of ART initiation, and increases considerably after 12 months \[[@CIT0011],[@CIT0032],[@CIT0044]\]. For example, the prevalence of lipodystrophy was 0.8% in a study in Thailand after six months of ART \[[@CIT0032]\], 34% in a study in Rwanda after 16 months of ART \[[@CIT0011]\], and 63% in a study in Cambodia after four years of ART \[[@CIT0044]\]. However, this trend has not been observed in all studies, and newer studies indicate that it is actually isolated lipoatrophy, not lipohypertrophy that progresses over time with tNRTIs (thymidine-based) \[[@CIT0013],[@CIT0045]\]. In contrast, some cohort studies have noted that lipoatrophy persists but does not increase with time \[[@CIT0046]\], while some trials have demonstrated that ARVs may be associated with increases in limb fat over time \[[@CIT0047]\].

In a South African study in 2670 HIV-infected adults initiating HAART, the incidence of lipodystrophy was 1.4 per 100 person-years, but nearly doubled to 2.6 per 100 person-years when the follow-up period excluded the first six months of therapy \[[@CIT0048]\]. Thus, ART type and duration need to be considered when comparing rates of lipodystrophy across studies. Some studies have reported the prevalence of lipoatrophy, lipohypertrophy and a mixed syndrome separately, and are presented in [Table 1](#T0001){ref-type="table"} \[[@CIT0011],[@CIT0012],[@CIT0033],[@CIT0049]--[@CIT0051]\].

###### 

Prevalence of lipohypertrophy, lipoatrophy and mixed syndrome in low and middle-income countries versus high-income countries

  Lipodystrophy         Africa \[[@CIT0011],[@CIT0033],[@CIT0034],[@CIT0043],[@CIT0049]\]   Asia \[[@CIT0031],[@CIT0032],[@CIT0050],[@CIT0051],[@CIT0161]\]   Latin America \[[@CIT0039],[@CIT0162]\]   High-income \[[@CIT0052],[@CIT0124],[@CIT0163],[@CIT0164]\]
  --------------------- ------------------------------------------------------------------- ----------------------------------------------------------------- ----------------------------------------- -------------------------------------------------------------
  Lipohypertrophy (%)   4.9--24.1                                                           3.6--53                                                           15.0--43.0                                7.4--47.0
  Lipoatrophy (%)       2.0--9.8                                                            0.8--72.4                                                         17.3--20.7                                16.4--43.0
  Mixed Syndrome (%)    2.5--33.0                                                           22.7--26.8                                                        34.0--46.7                                12.0--33.0

In a study of 180 HIV-infected adults from Brazil, sex-specific differences in the prevalence of different lipodystrophy syndromes were observed. Women were more likely to develop lipohypertrophy (43%) or mixed syndrome (40%), while men presented with a similar prevalence for all three lipodystrophy syndromes (34% lipoatrophy, 32% lipohypertrophy, 34% mixed syndrome) \[[@CIT0039]\]. The propensity of women to lipohypertrophy has also been observed in high-income countries \[[@CIT0052]\].

In contrast to lower-income countries, the prevalence of lipoatrophy is decreasing in high-income countries, as older drug regimens are being replaced with less toxic alternatives. For example, in the Swiss Cohort Study, there was a reduced risk of lipodystrophy in 6016 HIV-infected patients who initiated ART between 2003 and 2006 compared to the 5777 who started ART between 2000 and 2002 (*p*=0.02) \[[@CIT0022],[@CIT0053]\]. Zidovudine and stavudine use declined considerably during this period, from 88.5% and 4.2% (2000--2002) to 64.2% and 0.7% (2003--2006), respectively \[[@CIT0022]\]. This does not appear to be the case in the countries included in this review ([Figure 2](#F0002){ref-type="fig"}).

![Prevalence of lipodystrophy by year study started.](JIAS-18-19033-g002){#F0002}

The risk factors for fat redistribution syndromes and their relative importance also vary in different settings. For example, stavudine was used as standard therapy in Thailand as part of the GPO-VIR regimen \[[@CIT0028],[@CIT0029]\]. However it has not been used as frequently in Brazil, affecting the prevalence of lipoatrophy \[[@CIT0054]--[@CIT0059]\] as seen in [Table 1](#T0001){ref-type="table"}.

When comparing prevalence of lipodystrophy among studies, country-specific drug regimens, gender proportions and duration of ART use should also be considered.

Diagnosing lipodystrophy, lipoatrophy and lipohypertrophy {#S0003-S20002}
---------------------------------------------------------

Fat redistribution can be difficult to diagnose, particularly in settings where populations face the dual burden of obesity and undernutrition \[[@CIT0017],[@CIT0018]\]. There is no universal definition for lipodystrophy or body fat redistribution; the term "lipodystrophy" is often used to categorize any form of fat redistribution \[[@CIT0060]\]. As a result, the diagnosis, clinical management, and assessment of prevalence and aetiology are challenging. There is also a lack of concordance in the methods used to diagnose and monitor fat redistribution.

Lipodystrophy assessment methods include clinical examination, self-report, anthropometry, bioelectrical impedance analysis (BIA) and imaging techniques such as dual-energy X-ray absorptiometry (DEXA), magnetic resonance imaging (MRI) and computed tomography (CT).

### Anthropometry

Anthropometric measurements are the most common method of diagnosing lipodystrophy and include height, weight, body mass index (BMI), mid-upper arm circumference, waist circumference, hip circumference, waist-to-hip ratio and skinfold thickness measurements. These methods are non-invasive, relatively low-cost and interpretable, and compare well with more advanced techniques of assessing lipodystrophy, such as DEXA or MRI \[[@CIT0061]--[@CIT0063]\]. However, accurate and precise measurements require careful training and ongoing supervision of field workers \[[@CIT0064]\].

Standardized techniques are used to assess *skinfold thickness measurements*, including tricipital, bicipital, subscapular and suprailiac folds. The Durnin-Wormersley equation is often used to calculate body fat percentage from skinfold thickness measurements and has been validated in different populations, including African-Americans in the United States \[[@CIT0065]--[@CIT0067]\]. These tools are feasible and widely used in resource-limited settings \[[@CIT0068],[@CIT0069]\]. However, these equations have not been validated in HIV-infected populations, or in the context of lipodystrophy \[[@CIT0070],[@CIT0071]\].

### Standardized scales

The Carr Lipodystrophy Case Definition (LDCD) and the Lichtenstein HIV Outpatient Scale (HOPS) are standardized scales that are commonly used to assess lipodystrophy. LDCD uses a combination of demographic (age) and clinical (duration of HIV infection) information, metabolic parameters (anion gap, serum HDL cholesterol), anthropometry (waist-to-hip ratio) and radiologic assessments (DEXA, CT) to define lipodystrophy with 79% sensitivity and 80% specificity \[[@CIT0060]\]. The LDCD has also been expanded to include a scale for lipodystrophy severity \[[@CIT0072]\]. The required use of DEXA or CT limits the applicability of LDCD in resource-limited and field settings. The Lichtenstein HOPS scale was designed to assess lipodystrophy severity using standardized clinical evaluations, laboratory values and anthropometric measurements. It uses a more specific definition, including only moderate to severe lipodystrophy \[[@CIT0073]\]. However, the LDCD and HOPS do not differentiate among the three lipodystrophy syndromes.

Two studies from Africa demonstrated the importance of a standardized definition for different lipodystrophy syndromes. In Senegal, 180 HIV-infected adults on HAART for four to nine years were evaluated for lipodystrophy \[[@CIT0012]\]. The prevalence of mild to severe lipodystrophy diagnosed by physicians trained to evaluate lipodystrophy, lipohypertrophy and lipoatrophy using the Carr criteria was 65% (35.6% lipohypertrophy). The prevalence was 31% (14.5% lipohypertrophy) using a stricter definition which included only moderate to severe lipodystrophy, and 50% (no separate criteria for lipohypertrophy) using objective metabolic and anthropometric criteria \[[@CIT0012]\]. In a study in Cameroon, the prevalence of mild to severe lipodystrophy was 60%, compared to 18% using a stricter definition that only included moderate to severe lipodystrophy \[[@CIT0036]\]. In addition, a lack of concordance between clinical diagnosis and patient self-report of lipodystrophy frequently occurs, as seen in a study of 72 HIV-infected patients on HAART from Argentina. In this study, the use of two different patient questionnaires resulted in a diagnosis of body fat redistribution of 49% and 86%. When two different clinical criteria were used, the diagnosis of body fat redistribution was considerably lower, or 24% and 48%, respectively \[[@CIT0074]\].

### Body composition

Assessment is particularly important in HIV-infected individuals, since both HIV and ART are associated with changes in body composition and metabolic complications \[[@CIT0075],[@CIT0076]\]. Weight and BMI are crude measures of body composition, particularly at the individual level. However, some methods to assess body composition, such as DEXA, are prohibitively expensive and challenging to implement in resource-limited settings.

### Bioelectrical impedance

BIA is a non-invasive method of body composition assessment, which is more precise than skinfold thickness \[[@CIT0070]\]. The use of BIA has become widespread in body composition research due to its ease of use, portability and relatively low cost. BIA indirectly estimates different body tissues and compartments based on their conduction of a low-voltage, alternating current \[[@CIT0077]\]. BIA can be used to estimate total body water, fat-free body mass and body fat. BIA is useful in monitoring body changes over time and is highly correlated with other radiologic measures of body fat \[[@CIT0070]\]. However, the calculation of total fat is affected by fat distribution, making it a less accurate tool for evaluation of lipodystrophy \[[@CIT0071]\]. Some data suggest that BIA may not accurately reflect body composition changes in the context of HIV infection \[[@CIT0077]\], and BIA has not been extensively validated in the ART era.

### Other methods

Additional methods for assessment of body composition include imaging techniques such as DEXA, MRI and CT. However, DEXA cannot differentiate between subcutaneous and visceral fat, or evaluate facial lipoatrophy, one of the more disturbing morphologic complications of ART reported by patients \[[@CIT0078],[@CIT0079]\]. The error in measurement of body composition, particularly central fat, using DEXA may also be higher in the context of obesity \[[@CIT0080]\], suggesting that its applications may be limited in the context of lipohypertrophy assessment. In contrast to DEXA, which is unable to differentiate type of fat, MRI techniques require longer imaging time and specialized equipment, and CT has improved resolution but necessitates greater ionizing radiation exposure \[[@CIT0080]\]. Additional methods, such as MRI, are considered superior in assessment of body composition in the context of HIV, though are less widely available in lower-income settings. Other methods, such as ultrasound, have not been validated for lipodystrophy assessment \[[@CIT0081]\], and vary considerably on the operator \[[@CIT0082]\].

In a pilot study in Canada comparing BIA, skinfold measurements, and DEXA in assessment of percent body fat mass among 47 HIV-infected men receiving HAART \[[@CIT0083]\], the level of error and bias in BIA and skinfold methods were relatively low, compared to DEXA. Authors concluded that BIA and skinfold techniques are acceptable methods of monitoring total body fat mass in HIV-infected men on HAART as long as training and technique are standardized.

Lipodystrophy pathogenesis in HIV {#S0003-S20003}
---------------------------------

Lipodystrophy has a multi-factorial etiology, including HIV, effects of ART and host factors. Furthermore, lipoatrophy and lipohypertrophy likely have different pathogenic and genetic mechanisms, as reviewed elsewhere \[[@CIT0084],[@CIT0085]\], which pose challenges to clinical diagnosis and management. HIV infection may contribute to fat redistribution by infecting macrophages in adipose tissue, which release pro-inflammatory cytokines and enhance local inflammation \[[@CIT0086]\]. This is supported by increased tumour necrosis factor-alpha (TNF-α) expression observed in ART-naïve HIV-infected patients, a pro-inflammatory cytokine that initiates adipocyte apoptosis \[[@CIT0086],[@CIT0087]\].

Although the risk of developing lipodystrophy was thought to be associated with the type and duration of ART, as seen in many studies reviewed, this inadequately describes the association between ARTs and different lipodystrophy syndromes. *In vitro* and *in vivo* research has demonstrated effects of ARVs on functions of various organs, including adipose, liver and muscle. Lipodystrophy may develop as a result of the effects of specific NRTIs and PIs on lipid metabolism \[[@CIT0088],[@CIT0089]\]. PIs and NRTIs have been shown to alter regulation of genes involved in adipocyte differentiation, metabolism, cell cycle control and apoptosis. PIs are linked with adipocyte toxicity through several potential mechanisms \[[@CIT0090]\]. PIs induce or up-regulate genes that inhibit adipocyte differentiation and down-regulate adipogenesis-related transcription factors \[[@CIT0091],[@CIT0092]\], including interference with essential cellular transcription factors (e.g. SREBP-1c) \[[@CIT0092]\]. PIs inhibit pre-adipocyte differentiation by up-regulating the Wingless-related integration site (wnt)/B-catenin signalling pathway. One of the functions of this pathway is to inhibit adipogenic gene expression. Specifically, activation of the wnt/B-catenin signalling pathway prevents the induction of PPAR-γ \[[@CIT0093],[@CIT0094]\], a nuclear-receptor which regulators adipocyte differentiation and maintenance \[[@CIT0095]\]. PIs are also linked to reduced lipid accumulation in adipocytes, increased adipocyte apoptosis and induction of insulin resistance \[[@CIT0091]\].

NRTIs, stavudine and didanosine, are linked to inhibition of mitochondrial RNA transcription, depletion of mitochondrial DNA (mtDNA) and mitochondrial dysfunction, *via* inhibition of DNA polymerase γ \[[@CIT0096]\]. The toxic effects of NRTIs on mitochondrial function are likely a major contributor to the development of lipoatrophy \[[@CIT0096]--[@CIT0099]\]. NRTIs inhibit mtDNA *in vitro* with varying affinity, as per below:

zalcitabine\>didanosine\>stavudine\>zidovudine \>lamivudine=abacavir=tenofovir \[[@CIT0100]\]

*Most potent mtDNA inhibition to Least potent mtDNA inhibition*

Previous studies found that HIV-infected adults are less likely to develop lipoatrophy on tenofovir compared to stavudine, and tenofovir improved lipoatrophy in adults who previously developed lipoatrophy on stavudine \[[@CIT0101],[@CIT0102]\]. These findings are of particular relevance to resource-limited settings where older NRTIs (e.g. stavudine) are still relatively common \[[@CIT0103]\].

Natural history of lipodystrophy {#S0003-S20004}
--------------------------------

Lipodystrophy is often measured as a dichotomous outcome at a single time point in studies, rather than as a continuum of fat redistribution assessed prospectively. HIV-infected adults initiating ART often experience an increase in weight, trunk and limb fat during the first four to six months of therapy; after this point, trunk fat stabilizes and limb fat progressively decreases \[[@CIT0104],[@CIT0105]\]. This may be due to an initial period of immune reconstitution, followed by NRTI or PI dose-dependent adipocyte toxicity. In a study in Rwanda, participants taking stavudine-based HAART experienced a rapid increase in body weight during the first 6 to 12 months of treatment, followed by a progressive decline in body weight during the second year of therapy, with a median loss of 3.1 kg per year (IQR: −1.6 to −5.6; *p*\<0.01) \[[@CIT0106]\]. In a study from Uganda, during the first six months of primarily AZT-based ART initiated by 76 HIV-infected adults, total lean and fat mass, and arm, waist, hip and thigh circumferences significantly increased \[[@CIT0107]\]. The total lean mass plateaued 6 to 12 months post-ART initiation at an increased level compared to at the initiation of AZT-based ART. Abdomen, subscapular and thigh skinfold thicknesses continued to increase significantly \[[@CIT0107]\].

Lipoatrophy may be associated with overall weight loss in HIV-infected adults on ART. In a study of 705 HIV-infected patients initiating stavudine in Rwanda, lipoatrophy was associated with a 2.0 kg per year weight loss (95% CI: −0.6 to −3.4 kg; *p*\<0.01). Weight loss had a positive predictive value for lipoatrophy of 21% and 32% and a negative predictive value of 99% and 92% for men and women, respectively \[[@CIT0106]\]. In contrast, some research suggests that lipohypertrophy presents with physiologic processes similar to regaining weight after starvation, as seen in patients recovering from *anorexia nervosa* \[[@CIT0108]\]. Thus, this may indicate a restoration to health, rather than a disease process \[[@CIT0109]\].

Differentiating between HIV itself, immune reconstitution and ART toxicity in the aetiology of lipodystrophy needs to be further elucidated. Prospective studies are needed to examine changes in fat redistribution over time and progression of lipodystrophy, to inform prevention and clinical management of lipodystrophy in HIV-infected patients.

Risk factors of lipodystrophy {#S0003-S20005}
-----------------------------

Risk factors for lipodystrophy syndromes identified in studies from lower-income countries are summarized in [Table 2](#T0002){ref-type="table"}. Stavudine use, ART duration and female sex were risk factors for lipodystrophy and lipoatrophy. There were limited studies on lipohypertrophy and no risk factors were identified for mixed syndrome.

###### 

Risk factors for lipodystrophy identified in studies from low- and middle-income countries

  Variables     Lipodystrophy[a](#TF0001){ref-type="table-fn"}                                     Lipoatrophy                                                                        Lipohypertrophy
  ------------- ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------
  ARV           Stavudine use \[[@CIT0012],[@CIT0050]\]                                            Stavudine use \[[@CIT0011],[@CIT0042],[@CIT0062]\]                                 
                                                                                                   Indinavir use \[[@CIT0062]\]                                                       
                Duration of ART \[[@CIT0029],[@CIT0034],[@CIT0048]\]                               Duration of ART \[[@CIT0011]\]                                                     
  Demographic   Female sex \[[@CIT0027],[@CIT0029],[@CIT0032],[@CIT0048],[@CIT0049],[@CIT0051]\]   Female sex \[[@CIT0011],[@CIT0032],[@CIT0042],[@CIT0043],[@CIT0049],[@CIT0106]\]   
                                                                                                   Age \>40 years \[[@CIT0032]\]                                                      Younger age \[[@CIT0033]\]
  Nutritional                                                                                      Baseline BMI \>25 kg/m^2^ \[[@CIT0011]\]                                           
                                                                                                   Onset and rate of weight loss \[[@CIT0011]\]                                       
  Immune        Undetectable HIV RNA \[[@CIT0050]\]                                                                                                                                   

These studies identified risk factors for lipodystrophy and did not differentiate between types of lipodystrophy syndromes (i.e. lipoatrophy, lipohypertrophy and/or mixed syndrome). No risk factors were identified for mixed syndrome alone.

### Female sex

Several studies in lower-income countries have identified female sex as a risk factor for lipodystrophy. In a study of 2190 Rwandan HIV-infected patients initiating HAART, women had a 9.7 (HR: 9.7, 95% CI: 4.5--21.0, *p*\<0.05) times greater risk of developing lipoatrophy, compared to men \[[@CIT0043]\]. In a study in South Africa, the prevalence of lipoatrophy was 57% in women, compared to 13% in men (*p*\<0.05) \[[@CIT0049]\]. In some studies, female sex was the only significant risk factor for lipodystrophy, after adjusting for other variables \[[@CIT0042],[@CIT0049],[@CIT0106]\]. Women may also be less likely to receive adequate health care, education and support for HIV/AIDS \[[@CIT0008],[@CIT0110]\] and may be more vulnerable to the social impact of stigma and metabolic consequences \[[@CIT0008],[@CIT0110]\].

### Stavudine treatment

Stavudine is associated with severe dose-related side-effects of lipoatrophy, lactic acidosis and peripheral neuropathy \[[@CIT0032],[@CIT0048],[@CIT0099],[@CIT0111]\]. Based on these findings, the World Health Organization (WHO) recommended a lower maximum stavudine dose for all adults in 2007 (40--30 mg) \[[@CIT0036],[@CIT0051],[@CIT0112]\], and discontinued use in 2009 \[[@CIT0113]\]. Despite WHO recommendations, 14 (of 52) developing countries still used stavudine as a first-line HIV therapy in 2010, due to its comparatively lower cost (\~18 USD/year) and widespread availability \[[@CIT0016],[@CIT0114],[@CIT0115]\].

Stavudine toxicity continues to be a common cause of metabolic complications and regimen changes in resource-limited settings. HIV-infected patients taking stavudine had a 2.8 (OR: 2.8, 95% CI: 1.4--5.5, *p*\<0.05; OR: 4.7, 95% CI: 1.3--17.1, *p*=0.019) \[[@CIT0011],[@CIT0012]\] to 7.4 (OR: 7.4, 95% CI: 1.3--40.8, *p*=0.022) \[[@CIT0062]\] times greater odds of lipoatrophy, compared to other NRTI and ARV regimens. In Rwanda, the prevalence of lipodystrophy was three times higher in HIV-infected patients on stavudine, compared to zidovudine, which also causes lipoatrophy \[[@CIT0011]\]. In Cameroon, HIV-infected patients on stavudine were 5.5 times as likely to have lipoatrophy, compared to zidovudine (RR: 5.5, 95% CI: 1.3--23.5, *p*=0.02) \[[@CIT0036],[@CIT0116]\]. Stavudine toxicity also increases with duration and dose \[[@CIT0117]\]. In a cross-sectional study of 103 HIV-infected adults in Thailand, stavudine duration was associated with increased odds of lipodystrophy, with a 2% higher odds per month of treatment \[[@CIT0117]\]. Despite WHO recommendations and scientific evidence on its severe side-effects, however, its lower price and widespread availability makes stavudine replacement challenging in lower-income countries.

### Protease inhibitors

PIs were originally thought to be the main causative agent of lipodystrophy, though more recent evidence identified thymidine NRTIs as the leading contributor to ARV-related lipodystrophy. Lipohypertrophy has been attributed to PI use \[[@CIT0014],[@CIT0118]\].

There is limited research on PIs in lower-income countries, due in part to their prohibitive cost, compared to NRTIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs) \[[@CIT0114],[@CIT0119]\]. PIs are widely used in upper-middle-income countries \[[@CIT0030],[@CIT0062],[@CIT0120]--[@CIT0122]\]. In this review, studies in only three countries -- Thailand, India and Brazil -- evaluated the effects of PI use on lipodystrophy. In Thailand, 247 HIV-infected adults taking PIs had a higher prevalence of facial atrophy (50% vs. 30%) and female breast hypertrophy (52% vs. 12%), compared to non-PI ART \[[@CIT0062]\]. In India, patients who switched to a PI after immunologic failure on NNRTIs had a 10% incidence of lipodystrophy within the first year \[[@CIT0030]\]. In a cross-sectional study of 457 HIV-infected adults and adolescents in Brazil, longer PI use was associated with self-reported lipodystrophy \[[@CIT0122]\].

### NNRTIs

NNRTIs, particularly nevirapine, are used frequently in lower-income countries and are not commonly linked to lipodystrophy syndromes. In one study, nevirapine was associated with a 50% lower odds of lipoatrophy (OR 0.50, 95% CI: 0.26--0.95, *p*\<0.001) \[[@CIT0062]\].

### Other risk factors

Additional risk factors for lipodystrophy identified in the studies reviewed include: older age (\>40 years) \[[@CIT0032],[@CIT0073],[@CIT0123],[@CIT0124]\], greater baseline body weight at ARV initiation \[[@CIT0029],[@CIT0048]\], undetectable HIV RNA \[[@CIT0050]\], recent weight loss and faster rate of weight loss \[[@CIT0011]\]. Increased baseline weight and BMI are risk factors that should be carefully examined in settings characterized by concurrent obesity and undernutrition.

Implications of lipodystrophy {#S0003-S20006}
-----------------------------

The development of lipodystrophy is associated with cardiometabolic risk factors. In a study of 68 underweight (BMI \<18.0 kg/m^2^) HIV-infected adults initiating NRTIs in India, 19 to 25% (Diabetes Federation criteria versus National Cholesterol Education Program criteria) of participants developed new onset metabolic syndrome within six months of ART initiation \[[@CIT0125]\]. Patients with ART-induced lipodystrophy may also develop impaired glucose tolerance, insulin resistance, hyperlactatemia, dyslipidemia and increased inflammatory markers \[[@CIT0126],[@CIT0127]\]. Although the interrelationship between ART use, insulin resistance and lipodystrophy has been noted in several studies \[[@CIT0127]--[@CIT0129]\], the temporal relationship and biological mechanisms involved are not well-understood. Insulin resistance often precedes lipodystrophy, so it is thought to be involved in the pathogenesis and development of lipodystrophy \[[@CIT0127]\]; however, other studies have suggested that lipodystrophy contributes to the development of insulin resistance \[[@CIT0128],[@CIT0129]\].

Lipodystrophy is associated with a variety of metabolic disturbances, though the causal mechanisms are unknown \[[@CIT0050]\]. In a study in Thailand, 93% of HIV-infected patients with lipodystrophy had at least one metabolic abnormality \[[@CIT0130]\]. Lipodystrophy has been associated with increased triglycerides \[[@CIT0027]\], total cholesterol \[[@CIT0034],[@CIT0130]\] and elevated glucose \[[@CIT0130]\], but no associations have been found with HDL or LDL \[[@CIT0027]\]. Sex differences have been observed in the presentation of distinct metabolic risk profiles. For example, in a prospective study of 332 HIV-infected adults in Brazil, BMI was higher in HIV-infected women with lipodystrophy (*p*=0.001) but lower in HIV-infected men with lipodystrophy (*p*=0.04) \[[@CIT0037]\]. In contrast, HIV-infected men with lipodystrophy had lower HDL, compared to women \[[@CIT0037]\].

### Quality of life and ARV adherence

Lipodystrophy is also associated with psychological consequences \[[@CIT0131],[@CIT0132]\], reduced self-reported quality of life and ARV adherence \[[@CIT0008],[@CIT0059]\]. In a cross-sectional study in Thailand, 278 HIV-infected adults ranked the perceived severity of their lipodystrophy as mild (28%), moderate (54%) and severe (15%) \[[@CIT0130]\]. Self-reported lipodystrophy correlated poorly with clinical diagnosis of lipodystrophy (60% mild, 20% moderate, 2% severe) \[[@CIT0130]\]. Lipodystrophy has also been associated with lower reported quality of life. Patients have described the effects of lipodystrophy as disturbing and reported reduced satisfaction with their body image, self-esteem and social relationships, less confidence about their health and embarrassment due to body changes \[[@CIT0008],[@CIT0011],[@CIT0133]\]. These negative psychosocial consequences can also be associated with a fear of disclosure of HIV status and of stigma associated with HIV/AIDS. In a study of 50 adults in South India, there was a significant decrease in quality of life regarding financial (*p*\<0.045) and disclosure (*p*\<0.032) concerns between patients with lipodystrophy and without lipodystrophy \[[@CIT0134]\]. In a study in patients with lipodystrophy in Thailand, despite improvements seen on DEXA (after stavudine/didanosine substitution with tenofovir/lamivudine), there were no significant changes in patients' perceptions of their own lipodystrophy \[[@CIT0099]\]. In addition to the physical consequences of lipodystrophy, evaluating the impact of lipodystrophy on emotional well-being and quality of life is an important component to clinical management.

Management and treatment of lipodystrophy {#S0003-S20007}
-----------------------------------------

The primary therapy for severe lipodystrophy, particularly lipoatrophy, is a change in ARV regimen. There are also an increasing number of clinical management and treatment options for lipoatrophy and lipohypertrophy in high-income countries. However, there is comparatively little research on clinical management and treatment of lipodystrophy in lower-income countries.

### Lifestyle modifications

Diet and exercise can help reduce the progression of lipodystrophy, and mitigate its impact on health and quality of life. In a study in Rwanda, among HIV-infected individuals with lipodystrophy, a six-month exercise programme improved cardiorespiratory fitness, metabolic parameters and quality of life, compared to individuals not enrolled in exercise therapy \[[@CIT0133],[@CIT0135]\]. Participants also experienced a reduction in total cholesterol and insulin levels and improved body image, self-esteem, psychological well-being and social relationships \[[@CIT0133],[@CIT0135]\]. Several studies from Brazil have reported similar effects of lifestyle programmes \[[@CIT0136],[@CIT0137]\]. Further research is needed to determine the impact of exercise programmes on the treatment of lipodystrophy, and particularly on severe lipoatrophy, as exercise may exacerbate this condition \[[@CIT0138],[@CIT0139]\]. In contrast, in a study from Brazil where an intervention group received diet counselling every two months, there were no differences in anthropometric measurements between the intervention and control groups \[[@CIT0140]\].

### Dose reduction

In 2007, the WHO recommended a stavudine dose reduction from 40 to 30 mg for adults and adolescents \[[@CIT0036]\]. During this time period, researchers in Cameroon and South Africa monitored changes in lipodystrophy and metabolic parameters \[[@CIT0036],[@CIT0116]\]. In both cohort studies, the prevalence of lipoatrophy was significantly higher in patients who had taken the 40 mg dose of stavudine, compared to those who had only taken the 30-mg dose \[[@CIT0036],[@CIT0116]\]. In the cohort study in South Africa among 249 HIV-infected adults, patients taking the 40 mg dose of stavudine had a 12 times greater odds of moderate to severe lipoatrophy (OR: 11.8, 95% CI: 3.2--43.8, *p*\<0.05), compared to 30 mg \[[@CIT0116]\]. In a meta-analysis of trials comparing these doses of stavudine in high-income countries, there was strong evidence that the lower 30 mg dose of stavudine was associated with lower rates of side-effects (e.g. peripheral neuropathy) and discontinuation, and similar efficacy in suppressing HIV viral load, compared to the 40 mg dose. These findings informed the WHO recommendations for lower dose stavudine in 2007 \[[@CIT0141]\] and the subsequent discontinuation of stavudine due to severe side-effects in 2009 \[[@CIT0113]\].

### Regimen switches

Lipodystrophy and lipoatrophy have been the predominant reasons for stavudine substitutions. In a study in Thailand, 35 HIV-infected adults were switched from stavudine/didanosine to tenofovir/lamivudine. There was an increase in limb fat mass (+0.38 kg, *p*\<0.006) and total fat mass (+0.69 kg, *p*\<0.02), as measured by DEXA 48 weeks after the regimen change \[[@CIT0099]\]. In addition to improving lipoatrophy, switching from stavudine to tenofovir was associated with increased mtDNA copies (386--1537, *p*\<0.001) \[[@CIT0142]\] and decreased total cholesterol, LDL and triglycerides \[[@CIT0099],[@CIT0142],[@CIT0143]\].

Several studies in low-income and middle-income countries have examined the effects of stavudine substitution with zidovudine. In a study in Rwanda among HIV-infected adults with lipodystrophy who were switched to either zidovudine or tenofovir/abacavir, the zidovudine group had significantly greater weight loss three months after substitution, with a mean loss of 1.6 kg (−1.62±4.23 kg) by 12 months. The tenofovir/abacavir group had a stable body weight for the first three months and a small but significant weight increase by 12 months (+0.70±4.18 kg) \[[@CIT0144]\]. No studies to date have evaluated the efficacy of switching to NRTI-sparing regimens in low-income and middle-income countries. In high-income countries, this regimen change has been effective in maintaining HIV viral load suppression and reducing the risk of side-effects, including lipodystrophy, though NRTI-sparing regimens are not commonly used in clinical practice \[[@CIT0145],[@CIT0146]\].

Pregnant women {#S0003-S20008}
--------------

There is a major research gap in our understanding of lipodystrophy during pregnancy. Pregnancy is a time of many hormonal and metabolic changes that directly affect the health of the woman and foetus. During pregnancy, there is a transient increase in lipid parameters, which may be exacerbated with NRTI and PI use \[[@CIT0147],[@CIT0148]\]. Further research is warranted to understand how lipodystrophy presents during pregnancy, and the impact of lipodystrophy on maternal and neonatal health. Further understanding of lipid alterations and naturally occurring insulin sensitivity in early trimesters and insulin resistance later in pregnancy \[[@CIT0149]\] should inform ARV treatment options, particularly in resource-limited settings where perinatal HIV infection is common.

Discussion {#S0004}
==========

ART is the gold standard for HIV/AIDS treatment, based on its demonstrated benefits on disease progression, immune reconstitution and mortality. However, lipodystrophy, lipoatrophy, lipohypertrophy and a mixed syndrome are common metabolic complications of ART, and increases with ART type and duration. There is limited research on ART-related lipodystrophy in low- and middle-income countries, despite accounting for more than 95% of the burden of HIV/AIDS. Of the 90 studies reviewed among adults, only eight were published from five low-income countries and nine from two lower middle-income economies. These studies focused on lipodystrophy prevalence, risk factors and ART side-effects, reflecting the continued use of older toxic ART regimes such as stavudine. Further research is needed to characterize lipodystrophy, its implications and treatment options in lower-income countries.

The prevalence of lipodystrophy is considerable in low- and middle-income countries, with lipoatrophy specifically increasing with type and duration of therapy. In most studies, lipoatrophy developed after the first six months of therapy, particularly with use of stavudine. Despite WHO recommendations, 14 out of 52 developing countries still use stavudine as a first-line HIV therapy, due to its comparatively lower cost and widespread availability \[[@CIT0016],[@CIT0114],[@CIT0115]\]. Therefore, in addition to prevalent cases of lipoatrophy from past use of stavudine, there continue to be incident cases from continued stavudine use in resource-poor settings.

Lipodystrophy, lipoatrophy, lipohypertrophy and a mixed syndrome are all associated with increased risk of cardiometabolic complications, including hypertension, diabetes, insulin resistance and cardiovascular disease. Many studies reviewed highlighted the increased odds of developing metabolic syndrome with the presence of lipodystrophy \[[@CIT0150]--[@CIT0155]\]. Newer therapies, such as thiazolidinediones, target not just fat redistribution but also insulin resistance associated with lipodystrophy \[[@CIT0156]--[@CIT0158]\]. The incidence of metabolic complications from HAART and/or lipodystrophy are anticipated to increase, given the rapid sale-up of ARVs worldwide, the increasing number and lifespan of HIV-infected patients on long-term ART, and emergence of obesity and non-communicable diseases in settings with extensive HIV burden.

Improved prevention and timely resolution of lipodystrophy could impact health, psychosocial well-being, quality of life and adherence. The stigma associated with HIV in some developing countries is still severe, therefore external fat redistribution changes can significantly negatively impact an individual\'s quality of life and ART adherence \[[@CIT0008],[@CIT0131],[@CIT0134],[@CIT0159]\].

Lipodystrophy management is integral to HIV care and treatment, and warrants further investigation in low- and middle-income countries.

Limitations {#S0004-S20001}
-----------

There are several limitations in the studies reviewed. These include a lack of standard clinical definition of lipodystrophy syndromes, varying assessment methods, limited number of prospective studies to examine the effects of ART on lipodystrophy over time, small sample sizes, different combinations of ARV regimens and limited assessment of other nutritional, immunological and metabolic factors. Some of the aforementioned studies were conducted among HIV-infected patients with failed first-line therapy or in case-control studies where patients were selected based on lipodystrophy or other clinical conditions, which limits generalizability to other HIV-infected populations and settings \[[@CIT0030],[@CIT0120]\]. These limitations constrain the interpretability and comparability of findings across studies.

The lack of standard clinical definition and heterogeneous characterization of lipodystrophy pose challenges to examine the aetiologies and risk factors of lipoatrophy, lipohypertrophy and mixed syndrome. Most studies have examined these conditions together as a combined endpoint and had insufficient sample size to examine risk factors for each condition individually over time. Many studies cited the need for a universal standardized method to diagnose lipodystrophy syndromes, validated in both clinical and field settings, to compare findings across studies \[[@CIT0012],[@CIT0036]\].

Prospective studies are needed to examine the effects of ART on lipodystrophy over a sufficient period of time after ART initiation. Patterns of lipodystrophy are also dynamic and may change due to HIV infection itself, and other potential factors. Some factors that were rarely adjusted for in multivariate analyses include other nutritional deficiencies, micronutrient supplement use, opportunistic infections, other co-infections and access to health care services, which are important covariates that can confound the results of the studies reviewed and limit the ability to interpret findings on the relationships between HIV, ART and lipodystrophy.

Future research {#S0004-S20002}
---------------

Further research is needed to better understand fat redistribution syndromes in resource-limited settings. There is inadequate research on lipohypertrophy, a condition that unlike mixed syndrome or lipoatrophy is also found in HIV-uninfected populations. Lipohypertrophy may be linked to increased risk of metabolic abnormalities, as there is strong evidence that links visceral fat accumulation to non-communicable diseases such as diabetes and cardiovascular disease \[[@CIT0085],[@CIT0160]\]. However, there is limited data on risk factors for lipohypertrophy in HIV-infected populations on ART.

In low- and middle-income countries, HIV/AIDS, food insecurity, micronutrient deficiencies, other infectious diseases and underweight co-occur with the emergence of obesity and non-communicable diseases. Despite the extensive burden of malnutrition, few studies take malnutrition into consideration when evaluating lipodystrophy \[[@CIT0106]\]. Further research is needed on the role of nutrition in the aetiology and clinical management of lipodystrophy, including the interplay between nutrition, metabolic disease, lipodystrophy and HIV infection.

Conclusions {#S0005}
===========

HIV represents a serious threat to global health, and ART is the gold standard for HIV/AIDS care and treatment. However, adverse ART-related outcomes, including lipodystrophy, are common in low- and middle-income countries. This has considerable implications for risk of metabolic diseases, quality of life and adherence. As ART is rapidly scaled up worldwide and early HIV detection, ARV initiation and lifespans of infected individuals increase, the length of ARV exposure and burden of related metabolic complications are also expected to rise in low- and middle-income countries. Comprehensive evidence-based interventions are urgently needed to reduce the burden of HIV and lipodystrophy, and inform clinical management in resource-limited settings.
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Supplementary Tables
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###### 

Low-income countries

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Region                    Population              *N*    Study objective                                  Lipodystrophy, lipoatrophy, lipohypertrophy           Other findings
  ------------------------- ----------------------- ------ ------------------------------------------------ ----------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  **AFRICA**                                                                                                                                                      

  Prospective cohort                                                                                                                                              

  Benin \[[@CIT0033]\]      HIV+ initiating HAART   79     LD incidence and risk factors of NNRTIs          LD: 30% (11 mo)\                                      Significant weight gain on ART, 13% developed metabolic syndrome
                                                                                                            Mixed: 2.5%, LH: 24%, LA: 9%                          

  Uganda \[[@CIT0107]\]     HIV+ initiating HAART   76     Anthropometry, total fat, lean mass with AZT                                                           HIV+: increased lean and fat mass; arm, waist, hip and thigh circumferences; and abdomen, subscapular, thigh SFT at 6 mo vs. controls

  Cross-sectional                                                                                                                                                 

  Ethiopia \[[@CIT0154]\]   HIV+ on HAART \>1 y     356    Prevalence and risk factors of LD                LD: 68.3%                                             LA/LH risk factors: smoking, d4T, \>1 y ART

  Ethiopia \[[@CIT0152]\]   HIV+ on HAART           313    Prevalence of BFR and metabolic changes          LD: 12.1%                                             LD risk factors: ART \>12 mo

  Malawi \[[@CIT0165]\]     HIV+ on d4T for ≥6 mo   203    d4T toxicity and mtDNA/nDNA ratio                LD: 18% (25 mo)                                       No association between LD and mtDNA/nuclear DNA ratio

  **ASIA**                                                                                                                                                        

  Cross-sectional                                                                                                                                                 

  Cambodia \[[@CIT0044]\]   HIV+ initiating ART     467    Immunovirological ART outcomes, adverse events   LD: 63% (4 y)                                         d4T adverse events: BFR, dyslipidemia, increased liver enzymes, peripheral neuropathy

  Cambodia \[[@CIT0166]\]   HIV+ on ART ≥2 y        346    Prevalence and predictors of non-adherence                                                             Independent predictors of non-adherence: LD- related side-effects, rural residence, HIV disclosure to \<2 family members

  Retrospective                                                                                                                                                   

  Cambodia \[[@CIT0032]\]   HIV+ initiating d4T     2481   Long term toxicity (6 y) with d4T                LA: 0.8% (6 mo), 7% (1 y), 56.1% (3 y), 72.4% (6 y)   d4T Regimen change: 37.1% due to LD\
                                                                                                                                                                  Risk Factors: age \>40 y, female, CD4 \<200 cells/μL
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

WHO GDP \$1,025 or less. ABC: abacavir; ART: antiretroviral therapy; AZT: zidovudine; BFR: body fat redistribution; d4T: stavudine HAART: highly active antiretroviral therapy; HIV: human immunodeficiency virus; LA: lipoatrophy; LD: lipodystrophy; LH: lipohypertrophy; mo: months; SFT: skinfold thickness; TC: total cholesterol; TG: triglycerides; WC: waist circumference; WHR: waist to height ratio; y: years. Prevalence unless otherwise noted.

###### 

Lower middle-income countries

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country                              Population                                *N*   Study objective                                      Lipodystrophy, lipoatrophy, lipohypertrophy\*\*               Other findings
  ------------------------------------ ----------------------------------------- ----- ---------------------------------------------------- ------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------
  **AFRICA**                                                                                                                                                                                              

  Cross-sectional                                                                                                                                                                                         

  Cameroon \[[@CIT0012],[@CIT0036]\]   HIV+ adults on d4T or AZT ≥6 mo           249   LD prevalence, effect of lower d4T dose on LD        Mild-severe LD: 60%\                                          Odds of LD: higher in d4t vs. AZT and group on 40 mg d4T switched to 30 mg vs. 30 mg only
                                                                                                                                            Moderate-severe LD: 18%                                       

  **ASIA**                                                                                                                                                                                                

  Prospective cohort                                                                                                                                                                                      

  India \[[@CIT0167]\]                 HIV+ initiating NVP ART                   190   Effects of NVP on weight, BMI, body composition                                                                    Weight changes: At 6 mo, 22% lost mean 3.6 kg, 19% stable, 59% gained mean 6 kg. No differences in WHR ratio, BFR, or CD4 counts.

  India \[[@CIT0030]\]                 HIV+≥12 mo of RTV-boosted PI              91    Safety, tolerability, efficacy of PI vs. NNRTI       LD incidence: 10.4% in 1 y after NNRTI to PI regimen change   Adverse effects after switch: LD, nausea, peripheral neuropathy

  India \[[@CIT0125]\]                 HIV+ initiating ART                       68    Metabolic and BFR changes with ART                                                                                 6 mo on ART, 19.1% had new-onset metabolic syndrome; total body fat, body fat mass, lean body mass, SFT significantly increased

  India \[[@CIT0031]\]                 Malnourished HIV+ adults initiating ART   34    Clinical markers used to monitor BFR                 LA: 26%\                                                      More body weight changes diagnosed than self-reported; 28% men, 75% women
                                                                                                                                            LH: 24                                                        

  Cross-sectional                                                                                                                                                                                         

  India \[[@CIT0051]\]                 HIV+ on ART, HIV+ ART naïve, and HIV−     363   LD prevalence in rural patients receiving ART        LD: 60.7%, LH: 22.7%, LA: 51.1%, mixed: 22.7%                 Risk factors for LD/LA: female, ART duration;\
                                                                                                                                                                                                          BMI: HIV−\>HIV+ART+\>HIV+ART−

  India \[[@CIT0161]\]                 HIV+ adults on 2-drug ART or HAART        286   Long-term metabolic and BFR changes on ART           LA: 2.8% (21 mo)                                              37.5% with LA received 2 drug regimen, 50% received HAART, 12.5% both

  India \[[@CIT0061]\]                 HIV+ men, on ART vs. ART naïve            121   Objective LD definition w/regional fat mass ratios   LD: 54.3% *via* trunk fat/lower limb fat mass ratio \>2.28    Clinical diagnosis of LD with many FP/FN results. Triceps SFT/Abd SFT: poor specificity

  India \[[@CIT0134]\]                 HIV+ adults on HAART                      50    QoL among HIV+ adults with and without LD            LA: 42% (3.71 y)                                              Significant differences in financial (*p*\<0.045) and disclosure (*p*\<0.023) concerns with LD
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GDP per capita: \$1026 to \$4,035. ABC: abacavir; ART: antiretroviral therapy; AZT: zidovudine; BFR: body fat redistribution; d4T: stavudine; FN, false negative; FP, false positive; HAART: highly active antiretroviral therapy; HIV: Human Immunodeficiency Virus; LA: lipoatrophy; LD: lipodystrophy; LH: lipohypertrophy; mo: months; NVP: nevirapine; PI: protease inhibitor; QoL: quality of life; RTV: ritonavir; SFT: skinfold thickness; TC: total cholesterol; TDF: tenofovir; TG: triglycerides; WC: waist circumference; WHR: waist to height ratio; ZDV: zidovudine; y: year. Prevalence unless otherwise noted.

###### 

Upper middle-income countries

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country                            Population                                     *N*    Study objective                                       Lipodystrophy, lipoatrophy, lipohypertrophy                                                                        Other findings
  ---------------------------------- ---------------------------------------------- ------ ----------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **AFRICA**                                                                                                                                                                                                                                                        

  Prospective cohort                                                                                                                                                                                                                                                

  Botswana \[[@CIT0168]\]            HIV+ subtype C, initiating ART                 650    Efficacy of ZDV/ddI/3TC switched from d4T/3TC         Treatment-modifying LD: 36% (2 y)                                                                                  6.2 kg and 3 kg weight increase from baseline in HIV wasting and HIV non-wasting, respectively

  Botswana \[[@CIT0043]\]            HIV+ initiating d4T, NVP                       2190   Incidence, risk factors for d4T and NVP toxicity      LA prevalence requiring regimen change: 7.2% (18 mo)                                                               LA risk factors: female sex, 40 mg d4T

  Botswana \[[@CIT0034]\]            HIV+ on ART (100 LD, 50 non-LD), 50 HIV−       571    Prevalence of LD and HAART toxicity                   LD: 34% (LA: 9%, LH: 19%, mixed: 72%), 18 mo: 69.6%                                                                LD risk factors: urban residence, ART duration; LD associated with significantly higher TC, WHR

  Rwanda \[[@CIT0011]\]              HIV+ adults on ART for \>1 y                   409    Prevalence and risk factors of LD                     LD: 34.3% (16 mo), mixed: 19.6%, LH: 4.9%, LA: 9.8%                                                                LA risk factors: recent onset/faster rate weight loss, 3x higher LA with d4T vs. AZT, female sex

  Rwanda \[[@CIT0144]\]              HIV+ requiring d4T substitution for LA         114    Weight after d4T switch to ZDV or TDF/ABC                                                                                                                                Switch to ZDV: progressive weight loss (significant at 2 and 12 mo); Switch to TDF/ABC: stable body weight, increased slightly after 3 mo

  Rwanda \[[@CIT0133],[@CIT0135]\]   HIV+ with and without BFR, HIV−                100    Weight and QoL after 6 mo of exercise therapy                                                                                                                            Greater decline in WC, WHR; improved emotional stress, body image, self-esteem psychological well-being, social relationships, and independence in exercise group

  South Africa \[[@CIT0042]\]        HIV+ initiating ART                            9040   Long term incidence of d4T toxicity, risk factors     LA incidence: 7.3%/4.6% after 23.1 mo of d4T/non-d4T ART                                                           LA risk factors: d4t and female sex

  South Africa \[[@CIT0116]\]        HIV+ initiating ART                            3910   Efficacy and safety of 30 mg vs. 40 mg of d4T         LA incidence: \<2% (12 mo)                                                                                         No evidence of impaired viral suppression with 30 mg d4T; LA: Increased odds with 40 mg d4T

  South Africa \[[@CIT0004]\]        HIV-infected on HAART                          2815   ART toxicity and reasons for regimen change           LD prevalence: 8.3% (14.9 mo)                                                                                      HAART adverse effects: LD, lactic acidosis

  South Africa \[[@CIT0048]\]        HIV+ initiating HAART                          2679   ART toxicity and reasons for regimen change           LD prevalence requiring d4T substitution: 9% (3 y)                                                                 LD risk factors: female sex, ART ≥6 mo, d4T regimen change: 21% (9% due to LD)

  South Africa \[[@CIT0035]\]        HIV+ initiating ART                            230    Changes in perception and anthropometry               LD prevalence: 35% (12 mo)                                                                                         Significant discrepancy between BMI and patient\'s perception of weight

  South Africa \[[@CIT0049]\]        HIV+ initiating d4T ART                        42     Changes in BFR and metabolic factors on d4T           LD: 42.9% (20.5 mo) mixed: 33%, LH: 9.5%, LA: 9.5%                                                                 LD risk factors: greater triceps and iliac crest SFT at baseline

  Retrospective                                                                                                                                                                                                                                                     

  Rwanda \[[@CIT0106]\]              HIV+ initiating d4T                            705    Weight change with LA and efficacy of d4T             LA requiring regimen change: 12.2% (2 y)                                                                           Rapid weight increase in first 6--12 mo of ART, progressive decline in weight year 2

  Cross-sectional                                                                                                                                                                                                                                                   

  Rwanda \[[@CIT0021]\]              HIV+ ART naïve and HIV− controls               821    BFR in HIV− and HIV+, ART naïve women                                                                                                                                    Mean body weight, BMI (19% HIV+, 26% HIV−), total body fat by BIA, WHRs similar in both groups; no associations between CD4 counts and body composition

  Rwanda \[[@CIT0008],[@CIT0159]\]   HIV+BFR+ and HIV+ BFR−                         100    Relationship between BFR and QoL                                                                                                                                         HIV+BFR+ vs. HIV+BFR−: former with larger WHR, less satisfied with self-esteem, social life, body appearance, more emotional stress, ashamed in public places

  Senegal \[[@CIT0012]\]             HIV+ on HAART 4--9 y and HIV− controls         180    Prevalence, risk factors, metabolic disorders         LD: 65%, mild: 33.9%, severe: 31.1%; 2nd LD definition: 49.5%                                                      Lower BMI, skinfolds and greater WHRs and trunk/arm skinfold ratios on HAART

  Senegal \[[@CIT0169]\]             HIV+ on HAART                                  20     Perceptions of LD                                     LD: 31.1% (9--16 y), LA: 60%, LH: 25%, Combined: 15%                                                               Most unable to recognize changes as LD. LH tolerated better; excess weight sign of wealth

  Senegal \[[@CIT0170]\]             HIV+ women, ART naïve, d4T/AZT, LPV/r          744    Body composition (DEXA) of d4T/AZT vs. LPV/r                                                                                                                             D4T/AZT or LPV/r: more central fat mass (*p*\<0.01) and less leg fat mass (*p*\<0.01) than ART naïve. D4T: WHR greater, calf skinfold lower (*p*\<0.033) with increasing d4T time

  Senegal \[[@CIT0171]\]             HIV+ exposed to thymidine analogue             171    mtDNA haplotypes, metabolic changes                                                                                                                                      No significant associations between mtDNA haplogroups and lipoatrophy

  South Africa \[[@CIT0172]\]        HIV+ on HAART                                  479    Demand for surgical LA correction                     LD: 11.7%                                                                                                          5.9% considered stopping therapy due to LD, 47% consider surgery to correct LA/LD

  South Africa \[[@CIT0173]\]        HIV+, ART naïve women on ART                   83     VL, immune activation, adipose tissue                                                                                                                                    High VL women had a lower BMI, subcutaneous abdominal fat, WC, trunk fat measurements with DEXA vs. low VL group

  South Africa \[[@CIT0174]\]        HIV+ ART naïve, ART with LD+, ART LD−          39     PET glucose uptake by fat and muscle                                                                                                                                     Standardized uptake values (SUV): Higher in HAART patients with LD; SUV values for subcutaneous fat correlated with treatment duration and CD4 count

  **ASIA**                                                                                                                                                                                                                                                          

  Randomized trials                                                                                                                                                                                                                                                 

  China \[[@CIT0175]\]               HIV+ on d4T vs. switch to AZT after 24 weeks   199    Effects of switching from d4T to AZT after 24 weeks   LD: 18.4%, d4T to AZT group; LD: 0.6%, AZT only group                                                              

  Prospective cohort                                                                                                                                                                                                                                                

  China \[[@CIT0024]\]               AIDS+, ART naïve adults                        103    Efficacy/side-effects of HAART in AIDS patients       LD: 9.7% (12 mo)                                                                                                   HAART side-effects: peripheral neuropathy, gastrointestinal disorders, LD

  China \[[@CIT0025]\]               HIV+ adults initiating ART                     57     Long-term ART outcomes                                LD: 10.5% (72 mo)                                                                                                  44% changed from d4T to ddI (24 mo); 26.3% with elevated cholesterol and TG (72 mo)

  China \[[@CIT0026]\]               HIV+, ART naïve adults initiating ART          52     Adipocytokine and adipose distribution in HIV/LD      LD incidence: 2% (12 mo), 9.6% (18 mo), 52% (30 mo)                                                                Adiponectin incresed (6 mo) then decreased (18--30 mo) in LD+ group, no change in LD− group

  Thailand \[[@CIT0027]\]            HIV+ adults on HAART                           829    Genetic polymorphisms correlated with LA/LD           LA or LD: 32.6% (4 y)                                                                                              LA or LD risk factors: female sex, d4T (compared to AZT), Fas-670-AA

  Thailand \[[@CIT0028]\]            HIV+ initiating d4T/NVP                        152    Efficacy and adverse effects of d4T/3TC/NVP           LD: 35.5% (3 y)                                                                                                    Median % body weight increased 8.1% (1 y) then plateaued until end of study

  Thailand \[[@CIT0029]\]            HIV+ initiating d4T/NVP                        83     Efficacy and adverse effects of d4T/3TC/NVP           LD: 16.8% (2 y)                                                                                                    LD risk factors: low baseline body weight (≤50 kg), female sex, duration of treatment

  Thailand \[[@CIT0120]\]            HIV+, NRTIs to RTV boosted IDV/EFV             61     Metabolic disturbances and changes in BFR                                                                                                                                VAT mass increased by 20% (96 weeks) after switch; 4.1 and 15.9% increase in TC and TG, respectively, with 1 kg reduction in total limb fat mass at baseline

  Thailand \[[@CIT0121]\]            HIV+, NRTI to NRTI-sparing regimens            60     Effect of switch: NRTI to NRTI-sparing ART            All had LD                                                                                                         DEXA: mean total limb fat increase, mean lean limb mass loss (48 weeks) after switch

  Thailand \[[@CIT0099]\]            HIV+ 48 weeks after d4t/ddI to TDF/3TC         35     Effect of medication change on mtDNA                  LD: 54%                                                                                                            After switch, mtDNA content rose significantly, lipid factors reduced; reversal of LA on DEXA

  Cross-sectional                                                                                                                                                                                                                                                   

  Thailand \[[@CIT0155]\]            71% HIV+ on ART, 29% ART naïve                 580    Risk of metabolic syndrome with LD                    LD: 45.2%, LA: 41.9%, LH: 28.1% (2.6 y)                                                                            LD+: OR 1.8 (95% CI 1.0--3.0, *p*=0.032) of developing metabolic syndrome

  Thailand \[[@CIT0130]\]            HIV+ 33% treatment naïve, 77% ART              278    Prevalence, clinical characteristics of LD            LD: 21% in ART (43 mo)                                                                                             LD associations: higher CD4 counts and lower viral loads; 93% had 1+ metabolic abnormality

  Thailand \[[@CIT0062]\]            HIV+ART naïve, on PI ART, or non-PI ART        247    Prevalence of BFR and metabolic changes               LA: 21% temporal, 28% facial\                                                                                      ART treated: higher WC and WHR\
                                                                                                                                                 LH: 53% PI, 12.15% non-PI                                                                                          LA risk factors: Use of d4T and indinavir

  Thailand \[[@CIT0117]\]            HIV+ \>15 y old, exposed to d4T                103    LD risk factors                                       Absent to mild LD: 47%\                                                                                            Increased odds of LD: HLA-B\*4001 status, 2% increase of LD for every month of d4T
                                                                                                                                                 Moderate to severe LD: 53%                                                                                         

  Thailand \[[@CIT0050]\]            HIV+ initiating ART                            56     Prevalence, clinical, risk factors of LD              LD: 66.1%; mixed 26.8%, LA 35.7%, LH 3.6%                                                                          LD risk factors: undetectable HIV RNA, d4T

  **CENTRAL/SOUTH AMERICA**                                                                                                                                                                                                                                         

  Prospective cohort                                                                                                                                                                                                                                                

  Brazil \[[@CIT0037]\]              HIV+ on HAART                                  332    Identify risk factors for LD in HIV/AIDS              LD: 54.8% (5.7 y)                                                                                                  LD: higher BMI (women), lower BMI (men),\
                                                                                                                                                                                                                                                                    LD risk factors: d4T \>3 y, HAART \>4 y

  Brazil \[[@CIT0054]\]              HIV+LD+ and HIV− with PMMA fillers             266    Determine efficacy/safety of PMMA as facial filler                                                                                                                       90% of subjects were satisfied with treatment, significant improvements in self-esteem;\
                                                                                                                                                                                                                                                                    Adverse effects all transient and resolved spontaneously

  Brazil \[[@CIT0176]\]              HIV+ LD+ on HAART\>1 year                      187    Evaluate body fat content based on ART duration                                                                                                                          LD+ had 11 mm of additional abdominal fat after 1 y of ARVs vs. LD− Women had greater peripheral fat and men had 7.2 mm more visceral fat

  Brazil \[[@CIT0177]\]              HIV+LD+ with/without fibric acid therapy       53     Compare changes in lipid metabolism in LD adults                                                                                                                         No change in metabolic parameters at 6 mo post-nutritional counseling

  Brazil \[[@CIT0058]\]              HIV+ LA+, ART naive                            44     PMMA treatment on HIV disease progression                                                                                                                                Non-significant increase in patients with undetectable viral load (*p*=0.67) and significant increase in CD4 count (*p*=0.02) after PMMA treatment

  Brazil \[[@CIT0055]\]              AIDS+ with PMMA filling for LA                 49     Evaluate the use of PMMA to treat LA                                                                                                                                     Most patients on d4T or ZDV; side effects infrequent; 85.7% of patients satisfied after \>12 mo with PMMA

  Brazil \[[@CIT0178]\]              HIV+ LD+ on HAART for ≥18 mo                   24     Metformin\'s effects on HIV+LD+ adults                                                                                                                                   Mean weight loss: 2.2% of initial body weight (3 mo), 3.8% (6 mo), BMI reduction, WHR reduction, CT: total abdominal tissue reduced by 10.3% (6 mo)

  Brazil \[[@CIT0056]\]              HIV+ with facial LA                            20     Using Index for facial LA (ILA) to diagnose LA                                                                                                                           Good to excellent response to treatment for moderate to severe facial LA; short-term side effects resolved \<1 week and all within 6 mo

  Randomized trial                                                                                                                                                                                                                                                  

  Brazil \[[@CIT0140]\]              HIV+ on HAART for ≤12 mo                       50     Nutritional counseling on diet to prevent BFR                                                                                                                            No differences between intervention (dietary counseling) and control; both groups showed an increase in SSF from 1--8 mo (*p*\<0.001)

  Brazil \[[@CIT0179]\]              HIV+ LA+: NRTI-sparing for \>24 weeks          71     Rosiglitazone-induced fat recovery in LA                                                                                                                                 Limb fat (DEXA) increased significantly (448 g vs. 153 g) in LA group treated with rosiglitazone vs. placebo; facial LA scores changed significantly

  Brazil \[[@CIT0059]\]              HIV+ on ART eligible for PMMA for LA           40     Effects and impact of facial LA on patient QoL                                                                                                                           Slight improvement in medical outcomes, self-esteem, and Beck depression scale in PMMA group

  Brazil \[[@CIT0137]\]              HIV+ LD+ HL+ adults on HAART \>6 mo            30     Evaluate the effect of exercise therapy on LD                                                                                                                            Weight, BMI,% BF decreased similarly in both exercise/diet and diet groups; peak oxygen uptake improved only in exercise/diet

  Cross-sectional                                                                                                                                                                                                                                                   

  Argentina \[[@CIT0180]\]           HIV+ART naïve, ART LD+/LD−                     101    Markers of endothelial function in HIV+ adults                                                                                                                           LD group: highest TG, sVCAM-1 correlated with vWF (endothelial activation markers), % arm fat, CD4 T-cell counts, TG, ART naïve group: highest sVCAM-1

  Argentina \[[@CIT0074]\]           HIV+ on HAART                                  72     Congruency between methods measuring BFR                                                                                                                                 Questionnaire A vs. B: 86%/49% with BFR; Clinical criteria A vs. B: 48%/24%\
                                                                                                                                                                                                                                                                    Best assessment: DEXA ratio between trunk fat content and the leg fat content

  Brazil \[[@CIT0181]\]              HIV/AIDS+                                      958    LD and HTN prevalence                                 LD: 46.1% (HTN)\                                                                                                   Increased risk of HTN: age \>40 y, male sex, BMI \>25, TG \>150 mg/dL
                                                                                                                                                 LD: 47.7% (pre-HTN)                                                                                                

  Brazil \[[@CIT0182]\]              HIV+                                           819    Metabolic disturbances and LD prevalence              LD: 38.5%; LA: 45%, mixed: 42.9%, LH: 12.1%                                                                        Metabolic parameters: 86% had ≥1 metabolic disturbance (low HDL, high TG)

  Brazil \[[@CIT0183]\]              HIV+ receiving HAART                           620    ART on lipid profile pre- and post-HAART                                                                                                                                 Prevalence of DL/LD after HAART was 32.4% 30.1 mo vs. 11.3% before HAART\
                                                                                                                                                                                                                                                                    Higher prevalence of DL/LD with PI based regimen and d4T (*p*=0.006)

  Brazil \[[@CIT0184]\]              HIV+ on HAART \>1 y                            614    Genetic SNPs in estrogen receptor-a and -b in LD                                                                                                                         LA more common in men, LH more common in women (35.6% of all LD in women)\
                                                                                                                                                                                                                                                                    LA risk factors: age, European ancestry, PI use, AA homozygotes for ESR2 rs3020450

  Brazil \[[@CIT0122]\]              HIV/AIDS adolescents on HAART                  457    Analysis of patient self-perception of BFR                                                                                                                               64.3% reported perception of body changes (15% peripheral loss, 27% central gain); Perceived body changes significantly associated with duration of PI, NRTI, not NNRTI

  Brazil \[[@CIT0038]\]              HIV+ on HAART                                  410    Association between 4 polymorphisms and LD            Prevalence of LD: 53.4%                                                                                            No difference in genotype frequencies (LD/LD−); Adiponectin higher in specific alleles in LD

  Brazil \[[@CIT0185]\]              HIV+LD+, HIV+LD−HIV−LD−                        300    IL-18 and IFN-y gene polymorphisms (LD/LD−)                                                                                                                              LD: increased mRNA expression of inflammatory cytokines TNF, IL-6, IL-8; Increased odds of LD: IL-18-607A, Decreased odds: IL-18-607C; IFN-y: no difference (LD/LD−)

  Brazil \[[@CIT0186]\]              HIV+                                           256    Estimate hyperApoB prevalence, CV risk                                                                                                                                   Self-reported LD not associated with high apoB, prevalence of hyperApoB: 32.4% Hypercholesterolemia: 32%; TG: 47%; low HDL 47.6%, high LDL 47.4%

  Brazil \[[@CIT0136]\]              HIV/AIDS+ on HAART for ≥3 mo                   220    Physical activity and central fat relationship                                                                                                                           3 physical activity questionnaires: occupation, leisure sports, locomotion; significant negative correlation for LTPA with CSF

  Brazil \[[@CIT0039]\]              HIV or AIDS+ (96%)                             180    Assess LD prevalence and characteristics of LD        Women: LH: 43%, mixed: 40%; men: LA: 34%, mixed: 34%, LH: 32%                                                      Risk factors: female sex, AIDS duration \>8 y

  Brazil \[[@CIT0082]\]              HIV+LD+ and HIV+LD−                            179    U/S vs. clinical signs used to diagnose BFR                                                                                                                              LD risk factors: age, greater duration to ART; U/S predictors of LD: facial, subq abd, visceral body compartments; ROC curves: sensitivity 69.1%, specificity 94.9%

  Brazil \[[@CIT0187]\]              HIV+ART, HIV+ART naïve adults                  160    Compare intra-abdominal fat thickness by U/S                                                                                                                             No significant difference in subcutaneous adipose tissue between groups; positive correlation between intra-abdominal fat thickness and plasma TG, TC, glucose

  Brazil \[[@CIT0162]\]              HIV+LD+; HIV+LD− controls                      139    Different morphological alterations from LD           LA: 38.3% (25% facial); LH: 15% (8.3% abdomen); mixed: 46.7% (10% abdomen, face, UL, LL, 6.6% abdomen, face)       

  Brazil \[[@CIT0188]\]              HIV+LD+, HIV+LD−                               117    Frequency of TNF-a-e microsatellites in HIV                                                                                                                              TNF-308 G associated with OR: 28.40 of developing LD, protective effect of TNF-308G: 0.39, no significant association with TNF microsatellite presence polymorphisms

  Brazil \[[@CIT0189]\]              HIV+LD+, HIV+LD−                               69     LD+ and immune status correlation                                                                                                                                        Reduced CD4 T-cells: lower antibody production, lower anti-mLDL levels\
                                                                                                                                                                                                                                                                    LD correlated with increased mLDL, decreased anti-mLDL antibodies

  Brazil \[[@CIT0190]\]              HIV+LD+, HIV+LD−healthy controls (men)         44     Assess HIV-LD energy expenditure                                                                                                                                         HIV+LD+ vs. LD−: REE per kg lean mass significantly greater, body fat% lower, especially in leg; all HIV+: increased carbohydrate oxidation, lower lipid oxidation

  Brazil \[[@CIT0191]\]              AIDS+ patients on HAART                        74     Prevalence of LD after ≥5 y on HAART                  Self-reported LD: 51.4%, anthropometric: 66.2%, objective verification: 32.4%; LA: 62.5%, LH: 8.3%, mixed: 29.2%   

  Brazil \[[@CIT0070]\]              HIV+LD+, HIV+ LD−, controls (men)              44     Compare different methods to diagnose BFR                                                                                                                                BIA positively and significantly correlated with DEXA for MUAC and lean mass; SFT values correlated with DEXA only in controls

  Brazil \[[@CIT0040]\]              HIV+ on HAART                                  42     Assess physical activity in LD in HIV+ adults         LD: 42.9%                                                                                                          Active individuals had a 79% less chance of developing LD versus sedentary individuals

  Retrospective                                                                                                                                                                                                                                                     

  Brazil \[[@CIT0069]\]              HIV+ (PI: 47 NNRTI: 37)                        102    Factors associated with HIV related LD                LD: 59.3%                                                                                                          LD associated with increase in TC, not HDL nor TG

  Brazil \[192\]                     HIV+ starting on HAART                         233    Adverse effects of d4T                                LD: 6.9%                                                                                                           

  Chile \[[@CIT0041]\]               HIV+ on HAART for ≥10 y                        121    Clinical outcomes after 10 y of HAART                                                                                                                                    Average of 3.5 different ART regimens in 10 y due to drug toxicity (35%), allergy (9.2%) dyslipidemia (5.6%), lipodystrophy (5%)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GDP per capita: \$4,036--12,474. 3TC: lamivudine; ABC: abacavir; AIDS: acquired autoimmune deficiency syndrome; apoB: apolipoprotein B; ART: antiretroviral therapy; AZT: zidovudine; BFR: body fat redistribution; BMI: body mass index; CSF: central subcutaneous fat; CV: cardiovascular; d4T: stavudine; ddI: didanosine; DEXA: dual energy X-ray absorptiometry; EFV: efavirenz; HAART: highly active antiretroviral therapy; HIV: human immunodeficiency virus; IDV: indinavir; LA: lipoatrophy; LD: lipodystrophy; LH: lipohypertrophy; LTPA: leisure time physical activity; mtDNA: mitochondrial DNA; mo: months; MUAC: mid upper arm circumference; NVP: nevirapine; PET: positron emission tomography; PI: protease inhibitor; PMMA: polymethylmethacrylate; QoL: quality of life; REE: resting energy expenditure; ROC: receiver operating curve; SFT: skinfold thickness; TC: total cholesterol; TDF: tenofovir; TG: triglycerides; TNF: tumor necrosis factor; U/S: ultrasound; VAT: visceral adipose tissue; VL: viral load; WC: waist circumference; WHR: waist to height ratio; ZDV: zidovudine; y: year. Prevalence unless otherwise noted.
